Hexavalent vaccines for immunization in paediatric age

被引：22
作者：
Esposito, S. [1 ]
Tagliabue, C. [1 ]
Bosis, S. [1 ]
Ierardi, V. [1 ]
Gambino, M. [1 ]
Principi, N. [1 ]
机构：
[1] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Paediat High Intens Care Unit, I-20122 Milan, Italy
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2014年 / 20卷
关键词：
pertactin; hexavalent vaccine; combined vaccines; Anti-HBs; hepatitis B; pertussis; INFLUENZAE-TYPE-B; DTPA-HBV-IPV/HIB; INACTIVATED POLIO VIRUS; HIB CONJUGATE VACCINE; HEPATITIS-B; ACELLULAR PERTUSSIS; COMBINATION VACCINE; FULLY LIQUID; BOOSTER VACCINATION; COMBINED DIPHTHERIA;
D O I：
10.1111/1469-0691.12444
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Despite the potential for protection against a broad spectrum of pathogens, the availability of an increased number of effective vaccines could lead to a significant reduction in vaccination coverage as the result of issues with implementation of new vaccines within existing protocols. To overcome these problems, the development of combined vaccines has been promoted. The use of combined vaccines offers a number of potential benefits, including a reduction in the number of patient visits, reduced complications associated with multiple intramuscular injections, decreased costs of stocking and administering separate vaccines, and a lowering of the risk of delayed or missed vaccinations. The hexavalent vaccine includes antigens against diphtheria, tetanus, acellular pertussis (DTaP), hepatitis B (HBsAg), poliomyelitis (P1, P2, P3) and Haemophilus influenzae type B (Hib) infections. The primary goal of this review is to discuss the immunogenicity, efficacy, safety and tolerability of several hexavalent preparations that are either commercially available or still under development.
引用
收藏
页码：76 / 85
页数：10
相关论文
共 70 条
[1]   Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine:: First experiences and solutions to a serious and sensitive issue [J].
Ameñaca, F ;
Garcia-Sicilia, J ;
García-Corbeira, P ;
Boceta, R ;
Romero, A ;
Lopez, G ;
Dal-Ré, R .
PEDIATRICS, 2005, 116 (06) :1292-1298
[2]  
[Anonymous], 1999, MMWR Recomm Rep, V48, P1
[3]  
[Anonymous], EUR MED AG REC SUSP
[4]   Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age [J].
Arístegui, J ;
Dal-Ré, R ;
Díez-Delgado, J ;
Marés, J ;
Casanovas, JM ;
García-Corbeira, P ;
De Frutos, E ;
Van Esso, D ;
Verdaguer, J ;
De la Flor, J ;
Moraga, F ;
Boceta, R ;
García-Martínez, JA .
VACCINE, 2003, 21 (25-26) :3593-3600
[5]  
ASKEW GL, 1995, PEDIATRICS, V96, P889
[6]   Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule [J].
Avdicová, M ;
Prikazsky, V ;
Hudecková, H ;
Schuerman, L ;
Willems, P .
EUROPEAN JOURNAL OF PEDIATRICS, 2002, 161 (11) :581-587
[7]   A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children [J].
Becerra Aquino, Amalia Guadalupe ;
Gutierrez Brito, Maricruz ;
Aranza Doniz, Carlos E. ;
Galan Herrera, Juan Francisco ;
Macias, Mercedes ;
Zambrano, Betzana ;
Plennevaux, Eric ;
Santos-Lima, Eduardo .
VACCINE, 2012, 30 (45) :6492-6500
[8]  
Centers for Disease Prevention and Control, IMM SCHED EV EAS TO
[9]  
Ceyhan M, 2010, 5 AS C PED INF DIS 2
[10]   DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa™) A Review of its Use as Primary and Booster Vaccination [J].
Dhillon, Sohita .
DRUGS, 2010, 70 (08) :1021-1058
1234567